BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ISCI Announces Medical & Laboratory Director


2/21/2013 8:51:27 AM

PITTSTON, ME--(Marketwire - February 21, 2013) - YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the Company) announced today that The Integrative Stem Cell Institute (ISCI), a premier provider of point-of-care, stem cell-based therapies, has announced the appointment of Dr Eduardo Cervera Ceballos, MD as its Medical and Laboratory Director.

Dr Cervera, a licensed hematologist, is currently a Director at the National Cancer Institute in Mexico City. He is a graduate of the Autonomous University of the Yucatan and did his post-doctoral fellowship at the Regional Hospital Locarno and Hospital San Giovanni in Switzerland. Dr Cervera is a member of several prestigious associations, including the Internal Medicine Association of México, the European Society for Medical Oncology, the American Society of Clinical Oncology and the Oncology Society of Central American and the Caribbean. Dr Cervera is widely published with over 4 dozen articles, has developed curriculum for organizations such as American Society of Hematology, the American College of Physicians and spoken at several international conferences.

"Dr Cervera is a highly respected physician and researcher," says David Audley, CEO of the ISCI. "He brings years of clinical experience and laboratory expertise to the ISCI." Dr Cervera will also serve on the executive leadership of the ISCI and provide oversight to the laboratory and medical staff of the Institute. "Dr Cervera," continues Mr Audley, "will provide direct leadership to the medical and lab services that define our clinical studies. I have no doubt that under his oversight the ISCI becomes the standard for the field of regenerative medicine."

About Integrative Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at www.iscelli.com

SAFE HARBOR STATEMENT

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.


Contact:

The Integrative Stem Cell Institute
Contact:
Miranda Abrahams
Miranda@iscelli.com

Investor Contact
Atlanta Capital Partners, LLC
David Kugelman
(866) 692-6847
info@atlcp.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES